GlassScriptPhysician profile
Amanda Riley
NPI 1992126775
$8,762.74
in general payments reported to CMS, 2019-2025
45 companies · $2,042 in 2025
The $2,042 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $817 · 2022: $2,162 · 2023: $1,645 · 2024: $2,097 · 2025: $2,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,783.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,527.25 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $941.08 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $543.10 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $442.71 | 2021-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $375.71 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $364.26 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $346.42 | 2023-2025 | Tepezza, Repatha |
| Insulet Corporation | $341.05 | 2023-2025 | Omnipod |
| Corcept Therapeutics | $334.66 | 2021-2025 | Korlym |
| Amneal Pharmaceuticals LLC | $334.44 | 2021-2025 | Unithroid |
| Bigfoot Biomedical INC | $310.66 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $269.15 | 2021-2025 | |
| Abbott Laboratories | $202.42 | 2022-2025 | Freestyle Libre |
| Mannkind Corporation | $197.92 | 2022-2024 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.66 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $175.17 | 2022 | |
| Radius Health, INC. | $168.52 | 2024-2025 | Tymlos |
| Cequr Corporation | $165.21 | 2022-2025 | Cequr Simplicity |
| Dexcom, INC. | $164.11 | 2021-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $149.76 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $145.71 | 2021-2022 | |
| Antares Pharma, INC. | $143.74 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Alexion Pharmaceuticals, INC. | $103.30 | 2021-2025 | Strensiq |
| Embecta Corp. | $101.51 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Esperion Therapeutics, INC. | $88.08 | 2021-2022 | |
| Kyowa Kirin, INC. | $70.43 | 2024-2025 | Crysvita |
| Ascensia Diabetes Care US INC. | $60.31 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.97 | 2022-2023 | Cycloset |
| Verity Pharmaceuticals INC. | $55.72 | 2024-2025 | Tlando |
| Tolmar, INC. | $52.46 | 2024-2025 | Jatenzo |
| Ascendis Pharma Endocrinology INC | $50.18 | 2025 | Yorvipath |
| Madrigal Pharmaceuticals | $47.38 | 2025 | Rezdiffra |
| Ibsa Pharma INC. | $36.68 | 2023-2024 | Tirosint, Licart, Tirosint |
| Clarus Therapeutics INC. | $27.66 | 2021 | |
| Chiesi USA, INC. | $22.77 | 2025 | Mycapssa |
| Amarin Pharma, INC. | $22.56 | 2022 | |
| Glaxosmithkline, LLC. | $20.54 | 2025 | Arexvy, Shingrix |
| Halozyme INC | $19.92 | 2023 | |
| Boston Scientific Corporation | $19.00 | 2024 | |
| Pfizer INC. | $18.31 | 2024 | |
| Sequel Med Tech, LLC | $18.10 | 2025 | Twiist |
| Ultragenyx Pharmaceutical INC. | $17.29 | 2021 | |
| Zealand Pharma US, INC. | $16.57 | 2022 | |
| Medtronic, INC. | $13.21 | 2023 | Intellis Adaptivestim |
| Genentech USA, INC. | $2.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Riley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.